TipRanks
Lets talk about risk and the big picture. Its an appropriate time, as the big risk presented by the COVID-19 pandemic is finally receding thanks to the ongoing vaccination program. COVID is leaving behind an economy that was forced into shutdown one year ago while in the midst of a great expansion, boosted by the deregulation policies. While the new Biden Administration is busy reversing many Trump policies, at least for now the economy is rebounding. And this brings us to risk. A time of economic growth and rebound is a forgiving time to move toward risk investments, as general economic growth tends to lift everything. Two strategists from JPMorgan have recently chimed in, promoting the view that the markets fundamentals are still sound, and that small- to mid-cap sector is going to keep rising. First, on the general conditions, quant strategist Dubravko Lakos-Bujas wrote, Although the recent technical selloff and short squeeze is receiving a lot of attention, we believe the positive macro setup, improving fundamentals and COVID-19 outlook, strength of the US consumer, as well as the reflation theme remain the bigger forces at play. Not only should this drive further equity upside, but it remains favorable for continued rotation into economic reopening Building on this, Eduardo Lecubarr, chief of the Small/Mid-Cap Strategy team, sees opportunity for investors now, especially in the smaller value stocks. We stick to our view that 2021 will be a stockpickers paradise with big money-making opportunities if you are willing to go against the grain Many macro indicators did fall in January but SMid-Caps and equities in general continued to edge higher, Lecubarr noted. And if you are prone to look at high-risk, small- to mid-cap stocks, youll find yourself drawn to penny stocks. The risk involved with these plays scares off the faint hearted as very real problems like weak fundamentals or overwhelming headwinds could be masked by the low share prices. So, how should investors approach a potential penny stock investment? By taking a cue from the analyst community. These experts bring in-depth knowledge of the industries they cover and substantial experience to the table. Bearing this in mind, we used TipRanks database to find two compelling penny stocks, according to Wall Street analysts. Both tickers boast a Strong Buy consensus rating and could climb over 200% higher in the year ahead. CNS Pharmaceuticals (CNSP) We will start with CNS Pharmaceuticals, a biotechnology company with a focus on the treatment of glioblastomas, a class of aggressive tumors that attack the braid and spinal cord. These cancers, while rare, are almost always terminal, and CNS is working a new therapy designed to more effectively cross the blood-brain barrier to attack glioblastoma. Berubicin, CNSs flagship drug candidate, is an anthracycline, a potent class of chemotherapy drugs derived from the Streptomyces bacteria strains, and used in the treatment of a wide variety of cancers. Berubicin is the first drug in this class to show promise against glioblastoma cancers. The drug candidate has completed its Phase 1 clinical trial, in which 44% of patients showed a clinical response. This number included one patient who showed a Durable Complete Response, defined as a demonstrated lack of detectable cancer. Following the success of the Phase 1 study, CNS applied for, and received, FDA approval of its Investigational New Drug application. This gives the company the go-ahead to conduct a Phase 2 study on adult patients, an important next step in the development of the drug. CNS plans to start the mid-stage trial in 1Q21. Based on the potential of the companys asset in glioblastoma, and with its share price at $2.22, several analysts believe that now is the time to buy. Among the bulls is Brooklines 5-star analyst Kumaraguru Raja who takes a bullish stance on CNSP shares. Until now, the inability of anthracyclines to cross the blood brain barrier prevented its use for treatment of brain cancers. Berubicin is the first anthracycline to cross the blood-brain barrier in adults and access brain tumors Berubicin has promising clinical data in a Phase 1 trial in recurrent glioblastoma (rGBM) and has Orphan drug designation for treatment of malignant gliomas from the FDA. We model approval of Berubicin for treatment of recurrent glioblastoma in 2025 based on the Phase 2 data with 55% probability of success for approval. We model peak sales of $533 million in 2032, Raja opined. CNS pipeline also includes WP1244 (novel DNA binding agent) that is 500x more potent than daunorubicin in inhibiting tumor cell proliferation is expected to enter the clinic in 2021 In vivo testing in orthotopic models of brain cancer showed high uptake of WP1244 by brain and subsequent antitumor activity, the analyst added. To this end, Raja rates CNSP a Buy, and his $10 price target implies room for a stunning 350% upside potential in the next 12 months. (To watch Rajas track record, click here) What does the rest of the Street have to say? 3 Buys and 1 Hold add up to a Strong Buy consensus rating. Given the $8.33 average price target, shares could climb ~275% in the year ahead. (See CNSP stock analysis on TipRanks) aTyr Pharma (LIFE) The next stock were looking at, aTyr Pharma, has a focus on inflammatory disease. Its leading drug candidate, ATYR1923, is a Neuropilin-2 (NRP2) agonist, working through the receptor proteins expressed by the NRP2 gene. These pathways are important for cardiovascular development and disease, and play a role in the inflammatory lung disease pulmonary sarcoidosis. In December, the company reported that the drug candidate had completed enrollment of 36 patients in a Phase 1b/2a clinical trial, testing the drug in the treatment of pulmonary sarcoidosis. Results of the current study are expected in 3Q21, and will inform further trials of ATYR1923, including against other forms of inflammatory lung disease. On a more immediate note, in early January the company announced top-line results of another Phase 2 clinical involving ATRY1923 this time in the treatment of patients hospitalized with severe respiratory complications from COVID-19. The results were positive, showing that a single dose of ATYR1923 (at 3 mg/kg) resulted in a 5.5-day median recovery time. Overall, of the patients dosed in this manner, 83% saw recovery in less than one week. Covering LIFE for Roth Capital, 5-star analyst Zegbeh Jallah noted, We like the risk profile here, with two shots on goal, and updated data details from the COVID study is expected in the coming months. Also announced recently, is that data from aTyr's Pulmonary Sarcoidosis program, will be reported in 3Q21 the success of either of these studies could result in a doubling or more of the market cap as these opportunities appear to barely be accounted for by investors. In line with his optimistic approach, Jallah gives LIFE shares a Buy rating and his $15 price target suggests an impressive 277% potential upside for the coming year. (To watch Jallahs track record, click here) Other analysts are on the same page. With 2 additional Buy ratings, the word on the Street is that LIFE is a Strong Buy. On top of this, the average price target is $13.33, suggesting robust growth of ~236% from the current price of $3.97. (See LIFE stock analysis on TipRanks) To find good ideas for penny stocks trading at attractive valuations, visit TipRanks Best Stocks to Buy, a newly launched tool that unites all of TipRanks equity insights. Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.
See the rest here:
Bitcoin Next Week: Levels and Patterns to Watch - Yahoo Finance
- NYSE Plans Bitcoin Options, Bringing Another TradFi Giant Into Crypto - CoinDesk - May 31st, 2024 [May 31st, 2024]
- Mt Gox distributions may not be all doom and gloom for bitcoin - Blockworks - May 31st, 2024 [May 31st, 2024]
- Bitcoin ETFs are an 'astonishing success,' Goldman Sachs executive says - Quartz - May 31st, 2024 [May 31st, 2024]
- Franklin Templeton's Jenny Johnson on Bitcoin ETFs, RWA Tokenization and Blockchain's Potential for TradFi - CoinDesk - May 31st, 2024 [May 31st, 2024]
- Mastercard Crypto Credential Launches with "First Peer-to-Peer Pilot Transactions" - Bitcoin Magazine - May 31st, 2024 [May 31st, 2024]
- Is The MEV Monster Under Bitcoin's Bed? - Bitcoin Magazine - May 31st, 2024 [May 31st, 2024]
- The 2024 Bitcoin Halving Is Still Playing Out. Here's What to Expect Next. - The Motley Fool - May 31st, 2024 [May 31st, 2024]
- Ether Spot ETFs to See Much Lower Demand Than Bitcoin Versions, JPMorgan Says - CoinDesk - May 31st, 2024 [May 31st, 2024]
- Bitcoin market split as buying and selling volumes remain the same - CryptoSlate - May 31st, 2024 [May 31st, 2024]
- Bitcoin price today: flat at $67.7k amid rate fears; MT Gox risk eases By Investing.com - Investing.com - May 31st, 2024 [May 31st, 2024]
- Bitcoin Finds A New Consolidation Phase: Heres What to Expect from BTC Price Rally In H2 2024 - Coinpedia Fintech News - May 31st, 2024 [May 31st, 2024]
- Bitcoin needs '3.3% or lower' CPI print to reach new ATH - Cointelegraph - May 31st, 2024 [May 31st, 2024]
- This is How Bitcoin is Mirroring the 2015-2017 Bull Market - BeInCrypto - May 31st, 2024 [May 31st, 2024]
- This CEO Is Looking For The Next Generation Of Bitcoin Fund Managers - Bitcoin Magazine - May 31st, 2024 [May 31st, 2024]
- Bitcoin Price Drops. These Are the Levels to Watch. - Barron's - May 31st, 2024 [May 31st, 2024]
- Bitcoin Spot ETFs See 13 Consecutive Days of Net Inflows, Maintaining Strong Momentum - Cryptonews - May 31st, 2024 [May 31st, 2024]
- BlackRock Now Runs the World's Largest Bitcoin Fund - The Wall Street Journal - May 31st, 2024 [May 31st, 2024]
- $1,000,000 Bitcoin Price Is Possible Within the Next 18 Months, Says Strike CEO Jack Mallers Heres Why - The Daily Hodl - May 31st, 2024 [May 31st, 2024]
- Hackers Recover $3,000,000 in Lost Bitcoin From 11-Year Old Wallet After Owner Lost Password: Report - The Daily Hodl - May 31st, 2024 [May 31st, 2024]
- Researchers cracked open $1.6 million Bitcoin wallet after 20-character password was lost well worth the six months ... - Tom's Hardware - May 31st, 2024 [May 31st, 2024]
- Bitcoin drops to $67,000 level, and Gemini returns more than $2 billion to users - CNBC - May 31st, 2024 [May 31st, 2024]
- Bitcoin Price Slips. Why Mt. Gox Refunds Are Making the Market Nervous. - Barron's - May 31st, 2024 [May 31st, 2024]
- Fold Will Be Your Bitcoin Bank With CEO Will Reeves - Bitcoin Magazine - May 31st, 2024 [May 31st, 2024]
- Healthcare tech company shares surge 27% after announcing plans to buy bitcoin with cash reserves - The Block - May 31st, 2024 [May 31st, 2024]
- Binance: Bitcoin has a scalability issue, but there's hope in solutions - crypto.news - May 31st, 2024 [May 31st, 2024]
- Bitcoin on Cusp of Entering Parabolic Phase of the Cycle, Says Crypto Analyst Heres the Timeline - The Daily Hodl - May 31st, 2024 [May 31st, 2024]
- Here's What XRP Price Could be if Bitcoin Hits $155,000 - The Crypto Basic - May 31st, 2024 [May 31st, 2024]
- 41% of Voters Looking at Bitcoin and Crypto Due to Weakening Dollar and Political Tensions: Grayscale Survey - The Daily Hodl - May 31st, 2024 [May 31st, 2024]
- Ether will continue to outperform bitcoin in near term, says crypto asset manager - The Block - May 31st, 2024 [May 31st, 2024]
- US major predicts Bitcoin recognition as a weapon system as catalyst for $100 million price target - CryptoSlate - May 31st, 2024 [May 31st, 2024]
- Bitcoin Reaches Record High of $69,000, Recovering from 2022 Meltdown - The New York Times - March 10th, 2024 [March 10th, 2024]
- Is Bitcoin headed for $100k? What it could mean for US dollar. - IG - March 10th, 2024 [March 10th, 2024]
- Bitcoin Rallies To Record $70K, Prompts Coinbase Upgrade; BlackRock To Add BTC Exposure To $17.83 Billion Fund - Investor's Business Daily - March 10th, 2024 [March 10th, 2024]
- What Is Bitcoin 'Halving' and Does It Push Up the Cryptocurrency's Price? - Bloomberg - March 10th, 2024 [March 10th, 2024]
- What to Know About Bitcoins Record High in Latest Crypto Surge - The New York Times - March 10th, 2024 [March 10th, 2024]
- SEC's Gensler says crypto 'rife with abuses and fraud' as bitcoin surges to new all-time record - Yahoo Finance - March 10th, 2024 [March 10th, 2024]
- Rich Dad Poor Dad Author Robert Kiyosaki: Bitcoin 'on Fire' BTC Headed for $300K This Year Markets and Prices ... - Bitcoin.com News - March 10th, 2024 [March 10th, 2024]
- Bitcoin can top $150000 in the next 12-18 months, says Fundstrat's Tom Lee - CNBC - March 10th, 2024 [March 10th, 2024]
- Is This The Real $90 Trillion Reason Behind BlackRocks Huge Bitcoin ETF Flip That Triggered The Price Boom? - Forbes - March 10th, 2024 [March 10th, 2024]
- Bitcoin's Test of All-Time Highs Means Old Miners Are Cashing Out - CoinDesk - March 10th, 2024 [March 10th, 2024]
- Bitcoin Price Prediction: Can BTC Reach $100000? Forbes Advisor - Forbes - March 10th, 2024 [March 10th, 2024]
- Bitcoin hits new all-time high near $69,000 before tumbling - Yahoo Finance - March 10th, 2024 [March 10th, 2024]
- Bitcoin spikes above $70K, a record high, before fading - Yahoo Finance - March 10th, 2024 [March 10th, 2024]
- Bitcoin Ordinals Wallet Oyl Raises $3M With Arthur Hayes, BRC-20 Creator Domo Among Investors - CoinDesk - March 10th, 2024 [March 10th, 2024]
- Fear of bitcoin price 'triple top' dismissed by analysts following all-time high - TheStreet - March 10th, 2024 [March 10th, 2024]
- Here's why gold, bitcoin and stocks are all hitting new highs - Yahoo Finance - March 10th, 2024 [March 10th, 2024]
- Bitcoin vs. Ethereum: Which Is the Better Buy? - U.S News & World Report Money - March 10th, 2024 [March 10th, 2024]
- Crypto Analyst Predicts Bitcoin Could Surpass $330000, Breaking Historical Growth Patterns Markets and Prices ... - Bitcoin.com News - March 10th, 2024 [March 10th, 2024]
- Bitcoin is running out of enemies - Fortune - March 10th, 2024 [March 10th, 2024]
- Why is Bitcoin at an all-time high? - BBC.com - March 10th, 2024 [March 10th, 2024]
- Bitcoin tops $68,000 as it nears 2021 all-time high - CNBC - March 10th, 2024 [March 10th, 2024]
- BlackRock's Global Allocation Fund Eyes Spot Bitcoin ETFs, Expects Institutional Uptake to Drive BTC Above $600k - TradingView - March 10th, 2024 [March 10th, 2024]
- FT Cryptofinance: This time isn't different for bitcoin rally - Financial Times - March 10th, 2024 [March 10th, 2024]
- Coinbase Stock vs. Bitcoin: Which Should You Invest In? - Yahoo Finance - March 10th, 2024 [March 10th, 2024]
- ETC Group CEO on Bitcoin's wild ride to a new high and why Ethereum could be the next big thing - Yahoo Finance - March 10th, 2024 [March 10th, 2024]
- Miners continue money-conscious moves ahead of the Bitcoin halving - Blockworks - March 10th, 2024 [March 10th, 2024]
- Warren Buffett's danger to Apple, the truth about Bitcoin's record, and Nvidia's bubble: Markets news roundup - Quartz - March 10th, 2024 [March 10th, 2024]
- Warren Buffett Says He Wouldn't Pay $25 For All The Bitcoin In The World He Considers Crypto 'Rat Poison' And ... - Yahoo Finance - March 10th, 2024 [March 10th, 2024]
- Bitcoin breaks record: Will the crypto rally sustain? - DW (English) - March 10th, 2024 [March 10th, 2024]
- Bitcoin Hit a Record High. Here's What Might Happen Next - CoinDesk - March 10th, 2024 [March 10th, 2024]
- Bitcoin price falls below $39,000 as indicators suggest risk of a deeper correction, according to Bitfinex - The Block - January 25th, 2024 [January 25th, 2024]
- Bitcoin down 20% since ETFs approval, but may still see record high this year - MarketWatch - January 25th, 2024 [January 25th, 2024]
- Bitcoin briefly falls below $39,000 as post-ETF selling pressure continues - CNBC - January 25th, 2024 [January 25th, 2024]
- Bitcoin trims its losses after breaking below $39,000 to lowest level in 7 weeks - CNBC - January 25th, 2024 [January 25th, 2024]
- Bitwise publishes bitcoin ETF holdings address after on-chain sleuths uncover BlackRock's - Blockworks - January 25th, 2024 [January 25th, 2024]
- AI Agents Are Coming For CryptoPalantir Cofounder Issues Very Important Bitcoin, Ethereum, Solana And XRP Price Prediction - Forbes - January 25th, 2024 [January 25th, 2024]
- This Investing Phenomenon Could Be Why Bitcoin Prices Are Down After ETF Approval - Money - January 25th, 2024 [January 25th, 2024]
- Bitcoin Under $39K as ETF Debut Continues to Be a Sell-the-News Event - CoinDesk - January 25th, 2024 [January 25th, 2024]
- Blockchain, the tech behind bitcoin, may have found its 'killer use case' by keeping AI in check - CNBC - January 25th, 2024 [January 25th, 2024]
- Why Aren't There Options on the New Bitcoin ETFs Yet? - The Wall Street Journal - January 25th, 2024 [January 25th, 2024]
- Bitcoin ETFs to Likely Divert Users and Trading Volumes Away from CEXs, Says Anthony Bevan Bitcoin News - Bitcoin.com News - January 25th, 2024 [January 25th, 2024]
- Retail investors are worried bitcoin will plunge below $20000 this year, Deutsche Bank survey says - CNBC - January 25th, 2024 [January 25th, 2024]
- China's Currency Woes to Weigh on Bitcoin: Crypto Observer - CoinDesk - January 25th, 2024 [January 25th, 2024]
- Bitcoin ETF fee war spreads to Europe - Financial Times - January 25th, 2024 [January 25th, 2024]
- Bitcoin Bulls Buoyed by Report of FTX's $1B GBTC Sale - CoinDesk - January 25th, 2024 [January 25th, 2024]
- Despite the Bitcoin ETF Hype, Survey Says Investors Are Still Skeptical - Barron's - January 25th, 2024 [January 25th, 2024]
- Bitcoin ETFs aren't giving crypto a big boost just yet. Here's where the new funds stand - CNBC - January 25th, 2024 [January 25th, 2024]
- Why Bitcoin's 'relentless' selling will end in weeks - DLNews - January 25th, 2024 [January 25th, 2024]
- Bitcoin recovers above $40k amidst GBTC outflows, other ETF inflows - CryptoSlate - January 25th, 2024 [January 25th, 2024]
- These two drivers will fuel Bitcoin's rebound: 'It's happened often before' - DLNews - January 25th, 2024 [January 25th, 2024]